BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: PosthumaDeBoer J, Witlox MA, Kaspers GJ, van Royen BJ. Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature. Clin Exp Metastasis 2011;28:493-503. [PMID: 21461590 DOI: 10.1007/s10585-011-9384-x] [Cited by in Crossref: 125] [Cited by in F6Publishing: 122] [Article Influence: 11.4] [Reference Citation Analysis]
Number Citing Articles
1 Li Y, Zhao C, Yu Z, Chen J, She X, Li P, Liu C, Zhang Y, Feng J, Fu H, Wang B, Kuang L, Li L, Lv G, Wu M. Low expression of miR-381 is a favorite prognosis factor and enhances the chemosensitivity of osteosarcoma. Oncotarget 2016;7:68585-96. [PMID: 27612424 DOI: 10.18632/oncotarget.11861] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
2 Ma K, Zhang C, Huang MY, Guo YX, Hu GQ. Crosstalk between Beclin-1-dependent autophagy and caspase‑dependent apoptosis induced by tanshinone IIA in human osteosarcoma MG-63 cells. Oncol Rep 2016;36:1807-18. [PMID: 27499329 DOI: 10.3892/or.2016.5003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
3 Ma G, Zhang C, Luo W, Zhao JL, Wang X, Qian Y. Construction of microRNA-messenger networks for human osteosarcoma. J Cell Physiol 2019;234:14145-53. [PMID: 30666640 DOI: 10.1002/jcp.28107] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
4 Evola FR, Costarella L, Pavone V, Caff G, Cannavò L, Sessa A, Avondo S, Sessa G. Biomarkers of Osteosarcoma, Chondrosarcoma, and Ewing Sarcoma. Front Pharmacol 2017;8:150. [PMID: 28439237 DOI: 10.3389/fphar.2017.00150] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 8.2] [Reference Citation Analysis]
5 Sun K, Liao Q, Chen Z, Chen T, Zhang J. Expression of Livin and PlGF in human osteosarcoma is associated with tumor progression and clinical outcome. Oncol Lett 2018;16:4953-60. [PMID: 30214613 DOI: 10.3892/ol.2018.9239] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
6 Byrum SD, Washam CL, Montgomery CO, Tackett AJ, Suva LJ. Proteomic technologies for the study of osteosarcoma. Sarcoma 2012;2012:169416. [PMID: 22550414 DOI: 10.1155/2012/169416] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
7 Qu L, Liu B. Cyclooxygeanse-2 promotes metastasis in osteosarcoma. Cancer Cell Int 2015;15:69. [PMID: 26180515 DOI: 10.1186/s12935-015-0220-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
8 Wu F, Huang Y, Huang X, Fang S, Huang X, Huang X, Zhang Z, Shao Z. 99mTc-MIBI Scintigraphy for the Preoperative Assessment of Histological Response to Neoadjuvant Chemotherapy in Patients With Osteosarcoma: A Systematic Review and a Bivariate Meta-Analysis. Front Oncol 2020;10:762. [PMID: 32528883 DOI: 10.3389/fonc.2020.00762] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Katonis P, Datsis G, Karantanas A, Kampouroglou A, Lianoudakis S, Licoudis S, Papoutsopoulou E, Alpantaki K. Spinal osteosarcoma. Clin Med Insights Oncol 2013;7:199-208. [PMID: 24179411 DOI: 10.4137/CMO.S10099] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
10 Lindsey BA, Markel JE, Kleinerman ES. Osteosarcoma Overview. Rheumatol Ther 2017;4:25-43. [PMID: 27933467 DOI: 10.1007/s40744-016-0050-2] [Cited by in Crossref: 146] [Cited by in F6Publishing: 148] [Article Influence: 24.3] [Reference Citation Analysis]
11 Liu Y, Wang Y, Teng Z, Chen J, Li Y, Chen Z, Li Z, Zhang Z. Matrix metalloproteinase 9 expression and survival of patients with osteosarcoma: a meta-analysis. Eur J Cancer Care (Engl) 2017;26. [PMID: 26239566 DOI: 10.1111/ecc.12364] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
12 Yang F, Nam S, Zhao R, Tian Y, Liu L, Horne DA, Jove R. A novel synthetic derivative of the natural product berbamine inhibits cell viability and induces apoptosis of human osteosarcoma cells, associated with activation of JNK/AP-1 signaling. Cancer Biol Ther 2013;14:1024-31. [PMID: 24025361 DOI: 10.4161/cbt.26045] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
13 Kresse SH, Rydbeck H, Skårn M, Namløs HM, Barragan-Polania AH, Cleton-Jansen AM, Serra M, Liestøl K, Hogendoorn PC, Hovig E, Myklebost O, Meza-Zepeda LA. Integrative analysis reveals relationships of genetic and epigenetic alterations in osteosarcoma. PLoS One 2012;7:e48262. [PMID: 23144859 DOI: 10.1371/journal.pone.0048262] [Cited by in Crossref: 66] [Cited by in F6Publishing: 61] [Article Influence: 6.6] [Reference Citation Analysis]
14 Meng Q, Zheng M, Liu H, Song C, Zhang W, Yan J, Qin L, Liu X. TRAF6 regulates proliferation, apoptosis, and invasion of osteosarcoma cell. Mol Cell Biochem 2012;371:177-86. [PMID: 22886393 DOI: 10.1007/s11010-012-1434-4] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 4.1] [Reference Citation Analysis]
15 Salinas-Souza C, Oliveira ID, de Oliveira R, de Seixas Alves MT, Petrilli AS, Toledo SR. Establishment and cytogenetic characterization of a cell line from a pulmonary metastasis of osteosarcoma. Cytotechnology 2013;65:347-53. [PMID: 22833358 DOI: 10.1007/s10616-012-9487-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
16 Gu R, Li X, Yan X, Feng Z, Hu A. Circular RNA circ_0032462 Enhances Osteosarcoma Cell Progression by Promoting KIF3B Expression. Technol Cancer Res Treat 2020;19:1533033820943217. [PMID: 33153390 DOI: 10.1177/1533033820943217] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Jin H, Luo S, Wang Y, Liu C, Piao Z, Xu M, Guan W, Li Q, Zou H, Tan QY, Yang ZZ, Wang Y, Wang D, Xu CX. miR-135b Stimulates Osteosarcoma Recurrence and Lung Metastasis via Notch and Wnt/β-Catenin Signaling. Mol Ther Nucleic Acids 2017;8:111-22. [PMID: 28918013 DOI: 10.1016/j.omtn.2017.06.008] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
18 Hu C, Chen X, Wen J, Gong L, Liu Z, Wang J, Liang J, Hu F, Zhou Q, Wei L, Shen Y, Zhang W. Antitumor effect of focal adhesion kinase inhibitor PF562271 against human osteosarcoma in vitro and in vivo. Cancer Sci 2017;108:1347-56. [PMID: 28406574 DOI: 10.1111/cas.13256] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
19 Yamamoto N, Tsuchiya H. Chemotherapy for osteosarcoma – Where does it come from? What is it? Where is it going? Expert Opinion on Pharmacotherapy 2013;14:2183-93. [DOI: 10.1517/14656566.2013.827171] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.7] [Reference Citation Analysis]
20 Wang SN, Luo S, Liu C, Piao Z, Gou W, Wang Y, Guan W, Li Q, Zou H, Yang ZZ, Wang D, Wang Y, Xu M, Jin H, Xu CX. miR-491 Inhibits Osteosarcoma Lung Metastasis and Chemoresistance by Targeting αB-crystallin. Mol Ther 2017;25:2140-9. [PMID: 28648665 DOI: 10.1016/j.ymthe.2017.05.018] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 8.8] [Reference Citation Analysis]
21 Cheng Q, Yin G. Cullin-1 regulates MG63 cell proliferation and metastasis and is a novel prognostic marker of osteosarcoma. Int J Biol Markers 2017;32:e202-9. [PMID: 28315506 DOI: 10.5301/jbm.5000247] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
22 Mercatelli D, Bortolotti M, Bazzocchi A, Bolognesi A, Polito L. Immunoconjugates for Osteosarcoma Therapy: Preclinical Experiences and Future Perspectives. Biomedicines 2018;6:E19. [PMID: 29439419 DOI: 10.3390/biomedicines6010019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
23 Lin Z, Wu Z, Luo W. Chimeric Antigen Receptor T-Cell Therapy: The Light of Day for Osteosarcoma. Cancers (Basel) 2021;13:4469. [PMID: 34503279 DOI: 10.3390/cancers13174469] [Reference Citation Analysis]
24 Martin JW, Squire JA, Zielenska M. The genetics of osteosarcoma. Sarcoma 2012;2012:627254. [PMID: 22685381 DOI: 10.1155/2012/627254] [Cited by in Crossref: 110] [Cited by in F6Publishing: 97] [Article Influence: 11.0] [Reference Citation Analysis]
25 Zhang C, Ma K, Li WY. IL-6 Promotes Cancer Stemness and Oncogenicity in U2OS and MG-63 Osteosarcoma Cells by Upregulating the OPN-STAT3 Pathway. J Cancer 2019;10:6511-25. [PMID: 31777581 DOI: 10.7150/jca.29931] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
26 Zhang P, Dong L, Long H, Yang TT, Zhou Y, Fan QY, Ma BA. Homologous mesenchymal stem cells promote the emergence and growth of pulmonary metastases of the rat osteosarcoma cell line UMR-106. Oncol Lett 2014;8:127-32. [PMID: 24959232 DOI: 10.3892/ol.2014.2127] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
27 Wang LH, Tsai HC, Cheng YC, Lin CY, Huang YL, Tsai CH, Xu GH, Wang SW, Fong YC, Tang CH. CTGF promotes osteosarcoma angiogenesis by regulating miR-543/angiopoietin 2 signaling. Cancer Lett 2017;391:28-37. [PMID: 28108312 DOI: 10.1016/j.canlet.2017.01.013] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 8.6] [Reference Citation Analysis]
28 Namløs HM, Meza-Zepeda LA, Barøy T, Østensen IH, Kresse SH, Kuijjer ML, Serra M, Bürger H, Cleton-Jansen AM, Myklebost O. Modulation of the osteosarcoma expression phenotype by microRNAs. PLoS One. 2012;7:e48086. [PMID: 23133552 DOI: 10.1371/journal.pone.0048086] [Cited by in Crossref: 196] [Cited by in F6Publishing: 193] [Article Influence: 19.6] [Reference Citation Analysis]
29 Basu-Roy U, Basilico C, Mansukhani A. Perspectives on cancer stem cells in osteosarcoma. Cancer Lett 2013;338:158-67. [PMID: 22659734 DOI: 10.1016/j.canlet.2012.05.028] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 5.9] [Reference Citation Analysis]
30 Chiappetta C, Carletti R, Della Rocca C, Di Cristofano C. KMT2C modulates migration and invasion processes in osteosarcoma cell lines. Pathol Res Pract 2019;215:152534. [PMID: 31337554 DOI: 10.1016/j.prp.2019.152534] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
31 Yang X, Gao F, Zhang W, Li H, Huang X, Wei J, Bian J, Yang Y, Qian C, Sun M. “Star” miR-34a and CXCR4 antagonist based nanoplex for binary cooperative migration treatment against metastatic breast cancer. Journal of Controlled Release 2020;326:615-27. [DOI: 10.1016/j.jconrel.2020.07.029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
32 Yang J, Ma Z, Wang Y, Wang Z, Tian Y, Du Y, Bian W, Duan Y, Liu J. Necrosis of osteosarcoma cells induces the production and release of high-mobility group box 1 protein. Exp Ther Med 2018;15:461-6. [PMID: 29387198 DOI: 10.3892/etm.2017.5415] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
33 Mizushima E, Tsukahara T, Emori M, Murata K, Akamatsu A, Shibayama Y, Hamada S, Watanabe Y, Kaya M, Hirohashi Y, Kanaseki T, Nakatsugawa M, Kubo T, Yamashita T, Sato N, Torigoe T. Osteosarcoma-initiating cells show high aerobic glycolysis and attenuation of oxidative phosphorylation mediated by LIN28B. Cancer Sci 2020;111:36-46. [PMID: 31705593 DOI: 10.1111/cas.14229] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
34 Zhuo B, Li Y, Li Z, Qin H, Sun Q, Zhang F, Shen Y, Shi Y, Wang R. PI3K/Akt signaling mediated Hexokinase-2 expression inhibits cell apoptosis and promotes tumor growth in pediatric osteosarcoma. Biochem Biophys Res Commun 2015;464:401-6. [PMID: 26116768 DOI: 10.1016/j.bbrc.2015.06.092] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 4.7] [Reference Citation Analysis]
35 Huang G, Yu L, Cooper LJ, Hollomon M, Huls H, Kleinerman ES. Genetically modified T cells targeting interleukin-11 receptor α-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases. Cancer Res 2012;72:271-81. [PMID: 22075555 DOI: 10.1158/0008-5472.CAN-11-2778] [Cited by in Crossref: 70] [Cited by in F6Publishing: 49] [Article Influence: 6.4] [Reference Citation Analysis]
36 Wang W, Zhou X, Wei M. MicroRNA-144 suppresses osteosarcoma growth and metastasis by targeting ROCK1 and ROCK2. Oncotarget 2015;6:10297-308. [PMID: 25912304 DOI: 10.18632/oncotarget.3305] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 9.0] [Reference Citation Analysis]
37 Kuo HM, Tseng CC, Chen NF, Tai MH, Hung HC, Feng CW, Cheng SY, Huang SY, Jean YH, Wen ZH. MSP-4, an Antimicrobial Peptide, Induces Apoptosis via Activation of Extrinsic Fas/FasL- and Intrinsic Mitochondria-Mediated Pathways in One Osteosarcoma Cell Line. Mar Drugs 2018;16:E8. [PMID: 29301308 DOI: 10.3390/md16010008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
38 Liu B, Lu Y, Li J, Liu Y, Liu J, Wang W. Leukemia inhibitory factor promotes tumor growth and metastasis in human osteosarcoma via activating STAT3. APMIS 2015;123:837-46. [PMID: 26271643 DOI: 10.1111/apm.12427] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
39 Lopes LJS, Tesser-gamba F, Petrilli AS, de Seixas Alves MT, Garcia-filho RJ, Toledo SRC. MAPK pathways regulation by DUSP1 in the development of osteosarcoma: Potential markers and therapeutic targets. Mol Carcinog 2017;56:1630-41. [DOI: 10.1002/mc.22619] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
40 Osborne TS, Khanna C. A review of the association between osteosarcoma metastasis and protein translation. J Comp Pathol 2012;146:132-42. [PMID: 22297074 DOI: 10.1016/j.jcpa.2011.12.007] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 5.0] [Reference Citation Analysis]
41 Wang SW, Liu SC, Sun HL, Huang TY, Chan CH, Yang CY, Yeh HI, Huang YL, Chou WY, Lin YM, Tang CH. CCL5/CCR5 axis induces vascular endothelial growth factor-mediated tumor angiogenesis in human osteosarcoma microenvironment. Carcinogenesis. 2015;36:104-114. [PMID: 25330803 DOI: 10.1093/carcin/bgu218] [Cited by in Crossref: 73] [Cited by in F6Publishing: 74] [Article Influence: 9.1] [Reference Citation Analysis]
42 Tian Z, Guo B, Yu M, Wang C, Zhang H, Liang Q, Jiang K, Cao L. Upregulation of micro-ribonucleic acid-128 cooperating with downregulation of PTEN confers metastatic potential and unfavorable prognosis in patients with primary osteosarcoma. Onco Targets Ther 2014;7:1601-8. [PMID: 25246803 DOI: 10.2147/OTT.S67217] [Cited by in Crossref: 1] [Cited by in F6Publishing: 13] [Article Influence: 0.1] [Reference Citation Analysis]
43 Wei R, Deng Z, Su J. miR-217 targeting Wnt5a in osteosarcoma functions as a potential tumor suppressor. Biomedicine & Pharmacotherapy 2015;72:158-64. [DOI: 10.1016/j.biopha.2015.04.012] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
44 Wang D, Song Z, Wang Z. Common mechanism of pathogenesis in various types of metastatic osteosarcoma. Oncol Lett 2017;14:6307-13. [PMID: 29113282 DOI: 10.3892/ol.2017.6955] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
45 Zhang F, Yan T, Guo W, Sun K, Wang S, Bao X, Liu K, Zheng B, Zhang H, Ren T. Novel oncogene COPS3 interacts with Beclin1 and Raf-1 to regulate metastasis of osteosarcoma through autophagy. J Exp Clin Cancer Res 2018;37:135. [PMID: 29970115 DOI: 10.1186/s13046-018-0791-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
46 Gaspar N, Di Giannatale A, Geoerger B, Redini F, Corradini N, Enz-Werle N, Tirode F, Marec-Berard P, Gentet JC, Laurence V. Bone sarcomas: from biology to targeted therapies. Sarcoma. 2012;2012:301975. [PMID: 23226965 DOI: 10.1155/2012/301975] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
47 Ding M, Hu J, Ni J, Zheng Z, Song D, Wang J. Demethylation of microRNA-142 induced by demethylation agents plays a suppressive role in osteosarcoma cells. Oncol Lett 2015;9:2261-7. [PMID: 26137053 DOI: 10.3892/ol.2015.3036] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
48 Li P, Shi X, Xu Y, Zhong B, Lu Y, Sun Y. Interleukin-22 Promotes Osteosarcoma Cell Proliferation and Invasion via STAT3 Activation. Med Sci Monit 2018;24:7802-8. [PMID: 30381753 DOI: 10.12659/MSM.910962] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
49 Xu M, Jin H, Xu CX, Sun B, Song ZG, Bi WZ, Wang Y. miR-382 inhibits osteosarcoma metastasis and relapse by targeting Y box-binding protein 1. Mol Ther 2015;23:89-98. [PMID: 25292190 DOI: 10.1038/mt.2014.197] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 7.4] [Reference Citation Analysis]
50 Zhao JL, Chen FL, Zhou Q, Pan W, Wang XH, Xu J, Zhang SX, Ni LI, Yang HL. B7-H3 protein expression in a murine model of osteosarcoma. Oncol Lett 2016;12:383-6. [PMID: 27347155 DOI: 10.3892/ol.2016.4675] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
51 Pan Z, Cheng D, Wei X, Li S, Guo H, Yang Q. Chitooligosaccharides inhibit tumor progression and induce autophagy through the activation of the p53/mTOR pathway in osteosarcoma. Carbohydrate Polymers 2021;258:117596. [DOI: 10.1016/j.carbpol.2020.117596] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
52 Fu Z, Deng B, Liao Y, Shan L, Yin F, Wang Z, Zeng H, Zuo D, Hua Y, Cai Z. The anti-tumor effect of shikonin on osteosarcoma by inducing RIP1 and RIP3 dependent necroptosis. BMC Cancer 2013;13:580. [PMID: 24314238 DOI: 10.1186/1471-2407-13-580] [Cited by in Crossref: 91] [Cited by in F6Publishing: 92] [Article Influence: 10.1] [Reference Citation Analysis]
53 Gebhard C, Gabriel C, Walter I. Morphological and Immunohistochemical Characterization of Canine Osteosarcoma Spheroid Cell Cultures. Anat Histol Embryol 2016;45:219-30. [PMID: 26287450 DOI: 10.1111/ahe.12190] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
54 Shi JJ, Jia KH, Sun H, Gunosewoyo H, Yang F, Tang J, Luo J, Yu LF. Synthesis and Pharmacological Evaluation of σ2 Receptor Ligands Based on a 3-Alkoxyisoxazole Scaffold: Potential Antitumor Effects against Osteosarcoma. ChemMedChem 2021;16:524-36. [PMID: 32964625 DOI: 10.1002/cmdc.202000461] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
55 Wadhwa N. Osteosarcoma: Diagnostic dilemmas in histopathology and prognostic factors. Indian J Orthop 2014;48:247-54. [PMID: 24932029 DOI: 10.4103/0019-5413.132497] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
56 Zhang H, Yin Z, Ning K, Wang L, Guo R, Ji Z. Prognostic value of microRNA-223/epithelial cell transforming sequence 2 signaling in patients with osteosarcoma. Hum Pathol 2014;45:1430-6. [PMID: 24784921 DOI: 10.1016/j.humpath.2014.02.018] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
57 Durfee RA, Mohammed M, Luu HH. Review of Osteosarcoma and Current Management. Rheumatol Ther 2016;3:221-43. [PMID: 27761754 DOI: 10.1007/s40744-016-0046-y] [Cited by in Crossref: 164] [Cited by in F6Publishing: 169] [Article Influence: 27.3] [Reference Citation Analysis]
58 Asnafi AA, Behzad MM, Ghanavat M, Shahjahani M, Saki N. Singe nucleotide polymorphisms in osteosarcoma: Pathogenic effect and prognostic significance. Experimental and Molecular Pathology 2019;106:63-77. [DOI: 10.1016/j.yexmp.2018.12.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
59 Shi L, Xie C, Zhu J, Chen X. Downregulation of serum miR-194 predicts poor prognosis in osteosarcoma patients. Ann Diagn Pathol 2020;46:151488. [PMID: 32172218 DOI: 10.1016/j.anndiagpath.2020.151488] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
60 Zhou Y, Liu B, Wang M, Ni J. Endothelin-1 gene polymorphisms and risk of chemoresistant pediatric osteosarcoma. Pediatr Blood Cancer 2014;61:612-7. [PMID: 24123836 DOI: 10.1002/pbc.24790] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
61 Huang Y, Yao J, Zhu B, Zhang J, Sun T. Mitogen-activated protein kinase 7 promotes cell proliferation, migration and invasion in SOSP-M human osteosarcoma cell line. Tumori 2017;103:483-8. [PMID: 26350187 DOI: 10.5301/tj.5000399] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
62 De Martino V, Rossi M, Battafarano G, Pepe J, Minisola S, Del Fattore A. Extracellular Vesicles in Osteosarcoma: Antagonists or Therapeutic Agents? Int J Mol Sci 2021;22:12586. [PMID: 34830463 DOI: 10.3390/ijms222212586] [Reference Citation Analysis]
63 Benslimane-Ahmim Z, Pereira J, Lokajczyk A, Dizier B, Galy-Fauroux I, Fischer AM, Heymann D, Boisson-Vidal C. Osteoprotegerin regulates cancer cell migration through SDF-1/CXCR4 axis and promotes tumour development by increasing neovascularization. Cancer Lett 2017;395:11-9. [PMID: 28263839 DOI: 10.1016/j.canlet.2017.02.032] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
64 Liao YY, Tsai HC, Chou PY, Wang SW, Chen HT, Lin YM, Chiang IP, Chang TM, Hsu SK, Chou MC, Tang CH, Fong YC. CCL3 promotes angiogenesis by dysregulation of miR-374b/ VEGF-A axis in human osteosarcoma cells. Oncotarget 2016;7:4310-25. [PMID: 26713602 DOI: 10.18632/oncotarget.6708] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 8.0] [Reference Citation Analysis]
65 Noor S, Thornormóðsson HS, Zervas CT, Ly T, Gollogly J. Limb versus life: the outcomes of osteosarcoma in Cambodia. Int Orthop 2014;38:579-85. [PMID: 24305786 DOI: 10.1007/s00264-013-2173-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
66 Liu T, Ma Q, Zhang Y, Ke S, Yan K, Chen X, Wen Y, Fan Q, Qiu X. Interleukin-11 receptor α is overexpressed in human osteosarcoma, and near-infrared-labeled IL-11Rα imaging agent could detect osteosarcoma in mouse tumor xenografts. Tumour Biol. 2015;36:2369-2375. [PMID: 25524575 DOI: 10.1007/s13277-014-2844-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
67 Zhang K, Tian F, Zhang Y, Zhu Q, Xue N, Zhu H, Wang H, Guo X. MACC1 is involved in the regulation of proliferation, colony formation, invasion ability, cell cycle distribution, apoptosis and tumorigenicity by altering Akt signaling pathway in human osteosarcoma. Tumour Biol 2014;35:2537-48. [PMID: 24163085 DOI: 10.1007/s13277-013-1335-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
68 Qi J, Ma L, Wang X, Li Y, Wang K. Observation of significant biomarkers in osteosarcoma via integrating module- identification method with attract. Cancer Biomark 2017;20:87-93. [PMID: 28759958 DOI: 10.3233/CBM-170144] [Reference Citation Analysis]
69 Yamaguchi SI, Ueki A, Sugihara E, Onishi N, Yaguchi T, Kawakami Y, Horiuchi K, Morioka H, Matsumoto M, Nakamura M, Muto A, Toyama Y, Saya H, Shimizu T. Synergistic antiproliferative effect of imatinib and adriamycin in platelet-derived growth factor receptor-expressing osteosarcoma cells. Cancer Sci 2015;106:875-82. [PMID: 25940371 DOI: 10.1111/cas.12686] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
70 Li H, Fu X, Gao Y, Li X, Shen Y, Wang W. Small interfering RNA-mediated silencing of G-protein-coupled receptor 137 inhibits growth of osteosarcoma cells. J Bone Oncol 2018;11:17-22. [PMID: 29321966 DOI: 10.1016/j.jbo.2017.12.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
71 Amuti A, Liu D, Maimaiti A, Yu Y, Yasen Y, Ma H, Li R, Deng S, Pang F, Tian Y. Doxorubicin inhibits osteosarcoma progression by regulating circ_0000006/miR-646/ BDNF axis. J Orthop Surg Res 2021;16:645. [PMID: 34717683 DOI: 10.1186/s13018-021-02782-y] [Reference Citation Analysis]
72 Lou Z, Ren T, Peng X, Sun Y, Jiao G, Lu Q, Zhang S, Lu X, Guo W. Bortezomib induces apoptosis and autophagy in osteosarcoma cells through mitogen-activated protein kinase pathway in vitro. J Int Med Res 2013;41:1505-19. [DOI: 10.1177/0300060513490618] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
73 Na KY, Bacchini P, Bertoni F, Kim YW, Park Y. Syndecan-4 and fibronectin in osteosarcoma. Pathology 2012;44:325-30. [DOI: 10.1097/pat.0b013e328353447b] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
74 Wang B, Su Y, Yang Q, Lv D, Zhang W, Tang K, Wang H, Zhang R, Liu Y. Overexpression of Long Non-Coding RNA HOTAIR Promotes Tumor Growth and Metastasis in Human Osteosarcoma. Mol Cells 2015;38:432-40. [PMID: 25728753 DOI: 10.14348/molcells.2015.2327] [Cited by in Crossref: 50] [Cited by in F6Publishing: 54] [Article Influence: 7.1] [Reference Citation Analysis]
75 Ma X, Sun W, Shen J, Hua Y, Yin F, Sun M, Cai Z. Gelsolin promotes cell growth and invasion through the upregulation of p-AKT and p-P38 pathway in osteosarcoma. Tumor Biol 2016;37:7165-74. [DOI: 10.1007/s13277-015-4565-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
76 Gindin Y, Jiang Y, Francis P, Walker RL, Abaan OD, Zhu YJ, Meltzer PS. miR-23a impairs bone differentiation in osteosarcoma via down-regulation of GJA1. Front Genet 2015;6:233. [PMID: 26191074 DOI: 10.3389/fgene.2015.00233] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
77 Ge L, Zheng B, Li M, Niu L, Li Z. MicroRNA-497 suppresses osteosarcoma tumor growth in vitro and in vivo. Oncol Lett 2016;11:2207-12. [PMID: 26998150 DOI: 10.3892/ol.2016.4162] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
78 Cai H, Lin L, Cai H, Tang M, Wang Z. Prognostic evaluation of microRNA-210 expression in pediatric osteosarcoma. Med Oncol 2013;30. [DOI: 10.1007/s12032-013-0499-6] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 4.9] [Reference Citation Analysis]
79 Goudarzi A, Gokgoz N, Gill M, Pinnaduwage D, Merico D, Wunder JS, Andrulis IL. Protein kinase C epsilon and genetic networks in osteosarcoma metastasis. Cancers (Basel) 2013;5:372-403. [PMID: 24216982 DOI: 10.3390/cancers5020372] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
80 Zhao X, Wu Q, Gong X, Liu J, Ma Y. Osteosarcoma: a review of current and future therapeutic approaches. Biomed Eng Online 2021;20:24. [PMID: 33653371 DOI: 10.1186/s12938-021-00860-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
81 Xie J, Lei P, Hu Y. Small interfering RNA-induced inhibition of epithelial cell transforming sequence 2 suppresses the proliferation, migration and invasion of osteosarcoma cells. Exp Ther Med 2015;9:1881-6. [PMID: 26136909 DOI: 10.3892/etm.2015.2306] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
82 Salinas-Souza C, De Oliveira R, Alves MT, Garcia Filho RJ, Petrilli AS, Toledo SR. The metastatic behavior of osteosarcoma by gene expression and cytogenetic analyses. Hum Pathol 2013;44:2188-98. [PMID: 23845465 DOI: 10.1016/j.humpath.2013.04.013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
83 Jian C, Tu MJ, Ho PY, Duan Z, Zhang Q, Qiu JX, DeVere White RW, Wun T, Lara PN, Lam KS, Yu AX, Yu AM. Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models. Oncotarget 2017;8:30742-55. [PMID: 28415566 DOI: 10.18632/oncotarget.16372] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
84 Liu B, Xu L, Dai EN, Tian JX, Li JM. Anti-tumoral potential of MDA19 in human osteosarcoma via suppressing PI3K/Akt/mTOR signaling pathway. Biosci Rep 2018;38:BSR20181501. [PMID: 30442873 DOI: 10.1042/BSR20181501] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
85 Chiappetta C, Puggioni C, Carletti R, Petrozza V, Della Rocca C, Di Crisfofano C. The nuclear-cytoplasmic trafficking of a chromatin-modifying and remodelling protein (KMT2C), in osteosarcoma. Oncotarget 2018;9:30624-34. [PMID: 30093974 DOI: 10.18632/oncotarget.25755] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
86 Ferreira de Oliveira JMP, Remédios C, Oliveira H, Pinto P, Pinho F, Pinho S, Costa M, Santos C. Sulforaphane Induces DNA Damage and Mitotic Abnormalities in Human Osteosarcoma MG-63 Cells: Correlation with Cell Cycle Arrest and Apoptosis. Nutrition and Cancer 2013;66:325-34. [DOI: 10.1080/01635581.2014.864777] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
87 Senthamizhchelvan S, Hobbs RF, Song H, Frey EC, Zhang Z, Armour E, Wahl RL, Loeb DM, Sgouros G. Tumor dosimetry and response for 153Sm-ethylenediamine tetramethylene phosphonic acid therapy of high-risk osteosarcoma. J Nucl Med 2012;53:215-24. [PMID: 22251554 DOI: 10.2967/jnumed.111.096677] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
88 Zhu KP, Ma XL, Zhang CL. LncRNA ODRUL Contributes to Osteosarcoma Progression through the miR-3182/MMP2 Axis. Mol Ther 2017;25:2383-93. [PMID: 28750740 DOI: 10.1016/j.ymthe.2017.06.027] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 8.6] [Reference Citation Analysis]
89 Chen DJ, Lai Q, Zhu J, Wan Z, Liu H, Dai M, Guo R, Zhang B. Lumbar spinal canal osteosarcoma: A case report. Medicine (Baltimore) 2018;97:e11210. [PMID: 29924047 DOI: 10.1097/MD.0000000000011210] [Reference Citation Analysis]
90 Zhang Y, Zhao H, Xu W, Jiang D, Huang L, Li L. High Expression of PQBP1 and Low Expression of PCK2 are Associated with Metastasis and Recurrence of Osteosarcoma and Unfavorable Survival Outcomes of the Patients. J Cancer 2019;10:2091-101. [PMID: 31205570 DOI: 10.7150/jca.28480] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
91 Xu J, Wang Z, Liao Z, Dai D, Ma X. MicroRNA-150 functions as an antioncogenic regulator in osteosarcoma. Oncol Lett 2017;14:2483-90. [PMID: 28781686 DOI: 10.3892/ol.2017.6393] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
92 Jiang C, Fang X, Zhang H, Wang X, Li M, Jiang W, Tian F, Zhu L, Bian Z. AMD3100 combined with triptolide inhibit proliferation, invasion and metastasis and induce apoptosis of human U2OS osteosarcoma cells. Biomedicine & Pharmacotherapy 2017;86:677-85. [DOI: 10.1016/j.biopha.2016.12.055] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
93 Sadikovic B, Park PC, Selvarajah S, Zielenska M. Array comparative genomic hybridization in osteosarcoma. Methods Mol Biol 2013;973:227-47. [PMID: 23412794 DOI: 10.1007/978-1-62703-281-0_15] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
94 Lauvrak SU, Munthe E, Kresse SH, Stratford EW, Namløs HM, Meza-Zepeda LA, Myklebost O. Functional characterisation of osteosarcoma cell lines and identification of mRNAs and miRNAs associated with aggressive cancer phenotypes. Br J Cancer 2013;109:2228-36. [PMID: 24064976 DOI: 10.1038/bjc.2013.549] [Cited by in Crossref: 127] [Cited by in F6Publishing: 125] [Article Influence: 14.1] [Reference Citation Analysis]
95 Sun R, Shen J, Gao Y, Zhou Y, Yu Z, Hornicek F, Kan Q, Duan Z. Overexpression of EZH2 is associated with the poor prognosis in osteosarcoma and function analysis indicates a therapeutic potential. Oncotarget 2016;7:38333-46. [PMID: 27223261 DOI: 10.18632/oncotarget.9518] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 8.8] [Reference Citation Analysis]
96 Zhang K, Gao J, Ni Y. Screening of candidate key genes associated with human osteosarcoma using bioinformatics analysis. Oncol Lett 2017;14:2887-93. [PMID: 28928828 DOI: 10.3892/ol.2017.6519] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
97 Quartuccio N, Treglia G, Salsano M, Mattoli MV, Muoio B, Piccardo A, Lopci E, Cistaro A. The role of Fluorine-18-Fluorodeoxyglucose positron emission tomography in staging and restaging of patients with osteosarcoma. Radiol Oncol. 2013;47:97-102. [PMID: 23801904 DOI: 10.2478/raon-2013-0017] [Cited by in Crossref: 42] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
98 Meng Q, Zhao J, Liu H, Zhou G, Zhang W, Xu X, Zheng M. HMGB1 promotes cellular proliferation and invasion, suppresses cellular apoptosis in osteosarcoma. Tumour Biol 2014;35:12265-74. [PMID: 25168370 DOI: 10.1007/s13277-014-2535-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
99 Liang GH, Liu N, He MT, Yang J, Liang ZJ, Gao XJ, Rahhal AH, He QY, Zhang HT, Zha ZG. Transcriptional regulation of Runx2 by HSP90 controls osteosarcoma apoptosis via the AKT/GSK-3β/β-catenin signaling. J Cell Biochem 2018;119:948-59. [PMID: 28681940 DOI: 10.1002/jcb.26260] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
100 Jianwei Z, Enzhong B, Fan L, Jian L, Ning A. Effects of Kruppel-like factor 6 on osteosarcoma cell biological behavior. Tumor Biol 2013;34:1097-105. [DOI: 10.1007/s13277-013-0651-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
101 Zhu L, McManus MM, Hughes DP. Understanding the Biology of Bone Sarcoma from Early Initiating Events through Late Events in Metastasis and Disease Progression. Front Oncol 2013;3:230. [PMID: 24062983 DOI: 10.3389/fonc.2013.00230] [Cited by in Crossref: 37] [Cited by in F6Publishing: 48] [Article Influence: 4.1] [Reference Citation Analysis]
102 Del Mare S, Aqeilan RI. Tumor Suppressor WWOX inhibits osteosarcoma metastasis by modulating RUNX2 function. Sci Rep 2015;5:12959. [PMID: 26256646 DOI: 10.1038/srep12959] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
103 Fernanda Amary M, Ye H, Berisha F, Khatri B, Forbes G, Lehovsky K, Frezza AM, Behjati S, Tarpey P, Pillay N, Campbell PJ, Tirabosco R, Presneau N, Strauss SJ, Flanagan AM. Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neo-adjuvant chemotherapy. Cancer Med 2014;3:980-7. [PMID: 24861215 DOI: 10.1002/cam4.268] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 4.4] [Reference Citation Analysis]
104 Mu Y, Zhang H, Che L, Li K. Clinical significance of microRNA-183/Ezrin axis in judging the prognosis of patients with osteosarcoma. Med Oncol 2014;31:821. [PMID: 24352761 DOI: 10.1007/s12032-013-0821-3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
105 Chen XG, Ma L, Xu JX. Abnormal DNA methylation may contribute to the progression of osteosarcoma. Mol Med Rep 2018;17:193-9. [PMID: 29115427 DOI: 10.3892/mmr.2017.7869] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
106 Huang J, Shi Y, Li H, Tan D, Yang M, Wu X. Knockdown of receptor tyrosine kinase-like orphan receptor 2 inhibits cell proliferation and colony formation in osteosarcoma cells by inducing arrest in cell cycle progression. Oncol Lett 2015;10:3705-11. [PMID: 26788194 DOI: 10.3892/ol.2015.3797] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
107 Li Y, Lu J, Bai F, Xiao Y, Guo Y, Dong Z. Ginsenoside Rg3 Suppresses Proliferation and Induces Apoptosis in Human Osteosarcoma. Biomed Res Int 2018;2018:4306579. [PMID: 29750154 DOI: 10.1155/2018/4306579] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
108 Bazavar M, Fazli J, Valizadeh A, Ma B, Mohammadi E, Asemi Z, Alemi F, Maleki M, Xing S, Yousefi B. miR-192 enhances sensitivity of methotrexate drug to MG-63 osteosarcoma cancer cells. Pathology - Research and Practice 2020;216:153176. [DOI: 10.1016/j.prp.2020.153176] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
109 Yang W, He M, Zhao J, Wang Z. Association of ITGA3 gene polymorphisms with susceptibility and clinicopathological characteristics of osteosarcoma. Med Oncol 2014;31:826. [PMID: 24381140 DOI: 10.1007/s12032-013-0826-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
110 Ma Q, Zhou Y, Ma B, Chen X, Wen Y, Liu Y, Fan Q, Qiu X. The clinical value of CXCR4, HER2 and CD44 in human osteosarcoma: A pilot study. Oncol Lett 2012;3:797-801. [PMID: 22740996 DOI: 10.3892/ol.2012.558] [Cited by in Crossref: 1] [Cited by in F6Publishing: 12] [Article Influence: 0.1] [Reference Citation Analysis]
111 Yang G, Yuan J, Li K. EMT transcription factors: implication in osteosarcoma. Med Oncol. 2013;30:697. [PMID: 23975634 DOI: 10.1007/s12032-013-0697-2] [Cited by in Crossref: 71] [Cited by in F6Publishing: 81] [Article Influence: 7.9] [Reference Citation Analysis]
112 Hattinger CM, Fanelli M, Tavanti E, Vella S, Ferrari S, Picci P, Serra M. Advances in emerging drugs for osteosarcoma. Expert Opin Emerg Drugs 2015;20:495-514. [PMID: 26021401 DOI: 10.1517/14728214.2015.1051965] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 8.3] [Reference Citation Analysis]
113 Vos HI, Coenen MJ, Guchelaar HJ, Te Loo DM. The role of pharmacogenetics in the treatment of osteosarcoma. Drug Discov Today 2016;21:1775-86. [PMID: 27352631 DOI: 10.1016/j.drudis.2016.06.022] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 6.3] [Reference Citation Analysis]
114 Sheng G, Gao Y, Yang Y, Wu H. Osteosarcoma and Metastasis. Front Oncol 2021;11:780264. [PMID: 34956899 DOI: 10.3389/fonc.2021.780264] [Reference Citation Analysis]
115 Han Z, Li Q, Sun S, Zhao W, Shi L. Inactivated Sendai virus strain Tianjin induces apoptosis and autophagy through reactive oxygen species production in osteosarcoma MG-63 cells. J Cell Physiol 2019;234:4179-90. [PMID: 30146726 DOI: 10.1002/jcp.27176] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
116 Zhang K, Dong C, Chen M, Yang T, Wang X, Gao Y, Wang L, Wen Y, Chen G, Wang X, Yu X, Zhang Y, Wang P, Shang M, Han K, Zhou Y. Extracellular vesicle-mediated delivery of miR-101 inhibits lung metastasis in osteosarcoma. Theranostics 2020;10:411-25. [PMID: 31903129 DOI: 10.7150/thno.33482] [Cited by in Crossref: 18] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
117 Yang Q, Li S, Fu Z, Lin B, Zhou Z, Wang Z, Hua Y, Cai Z. Shikonin promotes adriamycin‑induced apoptosis by upregulating caspase‑3 and caspase‑8 in osteosarcoma. Mol Med Rep 2017;16:1347-52. [PMID: 28627658 DOI: 10.3892/mmr.2017.6729] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
118 Zhang H, Mai Q, Chen J. MicroRNA-210 is increased and it is required for dedifferentiation of osteosarcoma cell line. Cell Biol Int 2017;41:267-75. [PMID: 28032372 DOI: 10.1002/cbin.10721] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
119 Chiappetta C, Mancini M, Lessi F, Aretini P, De Gregorio V, Puggioni C, Carletti R, Petrozza V, Civita P, Franceschi S, Naccarato AG, Rocca CD, Mazzanti CM, Di Cristofano C. Whole-exome analysis in osteosarcoma to identify a personalized therapy. Oncotarget 2017;8:80416-28. [PMID: 29113313 DOI: 10.18632/oncotarget.19010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
120 Liu Y, Lv B, He Z, Zhou Y, Han C, Shi G, Gao R, Wang C, Yang L, Song H, Yuan W. Lysyl oxidase polymorphisms and susceptibility to osteosarcoma. PLoS One 2012;7:e41610. [PMID: 22911823 DOI: 10.1371/journal.pone.0041610] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
121 Wang F, Yu D, Liu Z, Wang R, Xu Y, Cui H, Zhao T. MiR-125b Functions as a Tumor Suppressor and Enhances Chemosensitivity to Cisplatin in Osteosarcoma. Technol Cancer Res Treat 2016;15:NP105-12. [DOI: 10.1177/1533034615618849] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
122 Liu MX, Liu QY, Liu Y, Cheng ZM, Liu L, Zhang L, Sun DH. Interleukin-35 suppresses antitumor activity of circulating CD8+ T cells in osteosarcoma patients. Connect Tissue Res 2019;60:367-75. [PMID: 30616389 DOI: 10.1080/03008207.2018.1552267] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
123 Wang X, Ning Y, Yang L, Liu H, Wu C, Wang S, Guo X. Diagnostic value of circulating microRNAs for osteosarcoma in Asian populations: a meta-analysis. Clin Exp Med 2017;17:175-83. [PMID: 27106278 DOI: 10.1007/s10238-016-0422-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
124 Namløs HM, Kresse SH, Müller CR, Henriksen J, Holdhus R, Sæter G, Bruland OS, Bjerkehagen B, Steen VM, Myklebost O. Global gene expression profiling of human osteosarcomas reveals metastasis-associated chemokine pattern. Sarcoma 2012;2012:639038. [PMID: 22518090 DOI: 10.1155/2012/639038] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
125 Caldarella C, Salsano M, Isgrò MA, Treglia G. The Role of Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Assessing the Response to Neoadjuvant Treatment in Patients with Osteosarcoma. Int J Mol Imaging 2012;2012:870301. [PMID: 23008768 DOI: 10.1155/2012/870301] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.2] [Reference Citation Analysis]
126 Angelini A, Ceci F, Castellucci P, Graziani T, Polverari G, Trovarelli G, Palmerini E, Ferrari S, Fanti S, Ruggieri P. The role of 18F-FDG PET/CT in the detection of osteosarcoma recurrence. Eur J Nucl Med Mol Imaging 2017;44:1712-20. [PMID: 28405727 DOI: 10.1007/s00259-017-3698-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]